GlassScriptPhysician profile
Meredith Marie Leduc
NPI 1366201071
$10,588.90
in general payments reported to CMS, 2019-2025
33 companies · $8,391 in 2025
The $8,391 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,197 · 2025: $8,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,627 · Travel and Lodging: $1,666 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,626.79 |
| Travel and Lodging | $1,666.13 |
| Education | $295.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,485.64 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $1,588.60 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $1,019.41 | 2024-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $517.67 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Jazz Pharmaceuticals INC. | $437.07 | 2024-2025 | |
| Eisai INC. | $395.85 | 2024-2025 | |
| Ucb, INC. | $394.83 | 2024-2025 | Briviact, Nayzilam, Rystiggo |
| Lundbeck LLC | $378.59 | 2024-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $360.75 | 2024-2025 | Xcopri |
| Argenx US, INC. | $286.18 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $281.35 | 2024-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $275.96 | 2024-2025 | Ingrezza |
| Catalyst Pharmaceuticals, INC. | $254.00 | 2024-2025 | |
| Pfizer INC. | $239.03 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $210.21 | 2025 | Ponvory |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $161.14 | 2024-2025 | Valtoco |
| Mallinckrodt Hospital Products INC. | $145.29 | 2025 | Acthar |
| Emd Serono, INC. | $129.08 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $116.23 | 2024-2025 | Nuplazid, Daybue |
| Lilly USA, LLC | $114.95 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $102.09 | 2025 | Ocrevus Zunovo, Evrysdi |
| Novartis Pharmaceuticals Corporation | $97.00 | 2024-2025 | |
| Tg Therapeutics, INC. | $90.91 | 2025 | |
| Biogen, INC. | $90.10 | 2025 | Vumerity, Tysabri |
| Tanabe Pharma America, INC. | $70.78 | 2024-2025 | Radicava |
| E.R. Squibb & Sons, L.L.C. | $66.24 | 2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $65.95 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $63.00 | 2024 | Hyqvia |
| Csl Behring | $56.59 | 2024-2025 | Hizentra |
| Mdd US Operations, LLC | $37.30 | 2025 | Gocovri |
| Celgene Corporation | $20.25 | 2025 | Zeposia |
| Servier Pharmaceuticals LLC | $18.58 | 2025 | |
| Cycle Pharmaceuticals INC | $18.28 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Leduc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.